Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Breast Neoplasms 331Neoplasms 231Prostatic Neoplasms 191Colorectal Neoplasms 149Lung Neoplasms 129Carcinoma, Non-Small-Cell Lung 105Leukemia, Myeloid, Acute 103Pancreatic Neoplasms 90Multiple Myeloma 90Precursor Cell Lymphoblastic Leukemia-Lymphoma 74Glioblastoma 71Brain Neoplasms 70Head and Neck Neoplasms 69Carcinoma, Hepatocellular 68Melanoma 64Squamous Cell Carcinoma of Head and Neck 62Neoplasm Metastasis 58Uterine Cervical Neoplasms 57Ovarian Neoplasms 55Stomach Neoplasms 50Rectal Neoplasms 50Hematologic Neoplasms 50Glioma 49Carcinoma, Renal Cell 47Sarcoma 46Recurrence 46Esophageal Neoplasms 44Myelodysplastic Syndromes 43Endometrial Neoplasms 43Motor Activity 42

Interventions

thymoglobulin 1fludarabine 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × beta-Thalassemia × 30 days × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡